Abstract
The aim of the present study was to develop and characterize rivastigmine loaded Human Serum Albumin (HSA) nanoparticles (NPs) for sustained release. Rivastigmine tartrate (RT) is a short acting cholinesterase inhibitor (ChEI) used for Alzheimer’s disease (AD). In the present study sustained release nanoparticulate formulation of RT was prepared, optimized (using 32 factorial design) and characterized (using biodegradable polymer HSA as a carrier). HSA NPs were prepared by desolvation-crosslinking technique using ethanol with variable drug/polymer ratios (1:1, 1:2, 1:3, and 1:5) and using glutaraldehyde as a crosslinking agent. All prepared nanoparticles were coated with polysorbate-80 to facilitate brain targeting via endocytosis. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using 32 factorial design. Among different ratios studied, 1:2 showed minimum PS of 83.71 ± 4.2 nm with highest PDE of 81.46 ± 0.76 %. FTIR interpretation showed that there is no interaction between the drug and excipients used, DSC thermograms indicated that RT was dispersed as an amorphous state in HSA NPs. SEM studies indicated that the drug was completely entrapped in HSA NPs. In vitro studies showed 55.59 ± 3.80% release of drug from HSA NPs in 12 h. The experimental results showed the suitability of HSA nanoparticles as a potential carrier for providing sustained delivery of RT.
Keywords: Desolvation-Crosslinking, Factorial design, Human Serum Albumin (HSA) nanoparticles, Rivastigmine Tartrate, Sustained release.
Current Drug Delivery
Title:Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Volume: 11 Issue: 3
Author(s): Amelia M. Avachat, Yogesh M. Oswal, Kishor N. Gujar and Rohit D. Shah
Affiliation:
Keywords: Desolvation-Crosslinking, Factorial design, Human Serum Albumin (HSA) nanoparticles, Rivastigmine Tartrate, Sustained release.
Abstract: The aim of the present study was to develop and characterize rivastigmine loaded Human Serum Albumin (HSA) nanoparticles (NPs) for sustained release. Rivastigmine tartrate (RT) is a short acting cholinesterase inhibitor (ChEI) used for Alzheimer’s disease (AD). In the present study sustained release nanoparticulate formulation of RT was prepared, optimized (using 32 factorial design) and characterized (using biodegradable polymer HSA as a carrier). HSA NPs were prepared by desolvation-crosslinking technique using ethanol with variable drug/polymer ratios (1:1, 1:2, 1:3, and 1:5) and using glutaraldehyde as a crosslinking agent. All prepared nanoparticles were coated with polysorbate-80 to facilitate brain targeting via endocytosis. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using 32 factorial design. Among different ratios studied, 1:2 showed minimum PS of 83.71 ± 4.2 nm with highest PDE of 81.46 ± 0.76 %. FTIR interpretation showed that there is no interaction between the drug and excipients used, DSC thermograms indicated that RT was dispersed as an amorphous state in HSA NPs. SEM studies indicated that the drug was completely entrapped in HSA NPs. In vitro studies showed 55.59 ± 3.80% release of drug from HSA NPs in 12 h. The experimental results showed the suitability of HSA nanoparticles as a potential carrier for providing sustained delivery of RT.
Export Options
About this article
Cite this article as:
Avachat M. Amelia, Oswal M. Yogesh, Gujar N. Kishor and Shah D. Rohit, Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles, Current Drug Delivery 2014; 11 (3) . https://dx.doi.org/10.2174/15672018113109990050
DOI https://dx.doi.org/10.2174/15672018113109990050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Anticonvulsant and Neurotoxicity Evaluation of Some Newer N-(2-benzoylbenzofuran-3-yl)-3-(substituted)-propanamide Analogs
Central Nervous System Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Editorial [Hot topic: Imaging of ABC Transporter Function and Expression (Guest Editors: Nicola Antonio Colabufo and Aren van Waarde)]
Current Topics in Medicinal Chemistry Therapeutic Drug Monitoring of Phenytoin by Simple, Rapid, Accurate, Highly Sensitive and Novel Method and Its Clinical Applications
Current Pharmaceutical Biotechnology Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Current Medicinal Chemistry Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules
Current Pharmaceutical Design Editorial [Hot topic: Chemical Agents Positively and Negatively Affecting the Central Nervous System (Guest Editors: Abel Santamaria & Mauricio Diaz-Munoz)]
Central Nervous System Agents in Medicinal Chemistry Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets mTOR, a Potential Target to Treat Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Ketamine: New Indications for an Old Drug
Current Drug Targets Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry Classical Neurotransmitters and Neuropeptides Involved in Generalized Epilepsy: A Focus on Antiepileptic Drugs
Current Medicinal Chemistry The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry